natgillin/translations-raw huggingface dataset:
In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants and young children aged from 6 months to less than 4 years. 
Kako bi se osiguralo točno doziranje to pakiranje treba propisivati dojenčadi i maloj djeci u dobi od 6 mjeseci do manje od 4 godine.
What Levetiracetam Actavis Group is and what it is used for What you need to know before you take Levetiracetam Actavis Group How to take Levetiracetam Actavis Group Possible side effects 
Što je Levetiracetam Actavis Group i za što se koristi Što morate znati prije nego počnete uzimati Levetiracetam Actavis Group Kako uzimati Levetiracetam Actavis Group
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinylestradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. 
Levetiracetam primijenjen u dozi od 1000 mg na dan nije utjecao na farmakokinetiku oralnih kontraceptiva (etinilestradiola i levonorgestrela); endokrini pokazatelji (luteinizirajući hormon i progesteron) ostali su nepromijenjeni.
Push the plunger down slowly to introduce air inside the bottle (Figure 3). 
Polako potisnite klip prema dolje kako biste unijeli zrak u bocu (slika 3).
The adverse reaction profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications. 
Profil nuspojava levetiracetama općenito je sličan u svim starosnim skupinama i u svim odobrenim indikacijama epilepsije.
These could be symptoms of an encephalopathy. 
To mogu biti simptomi oštećenja mozga.
Add-on therapy for infants aged 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg 
Dodatna terapija za dojenčad u dobi od 6 do 23 mjeseca, djecu (2 do 11 godina) i adolescente (12 do 17 godina) s manje od 50 kg tjelesne težine
Decrease in levetiracetam plasma concentrations has been observed during pregnancy. 
Tijekom trudnoće su primijećena sniženja koncentracija levetiracetama u plazmi.
The mean total body clearance was 0.96 ml/min/kg. 
Srednji ukupni tjelesni klirens iznosi 0,96 ml/min/kg.
Sixty of these patients were treated with levetiracetam in placebo-controlled studies. 
Šezdeset od tih bolesnika bilo je liječeno levetiracetamom u placebom kontroliranim ispitivanjima.
Maltitol liquid 
Tekući maltitol
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination using, for young adolescents, children and infants, using the following formula (Schwartz formula): 
Klirens kreatinina u ml/min/1,73 m2 može se za mlade adolescente, djecu i dojenčad procijeniti iz vrijednosti serumskoga kreatinina (mg/dl) s pomoću sljedeće formule (Schwartzova formula):
• hair loss, eczema, pruritus; 
• gubitak kose, ekcem, svrbež;
How to store Levetiracetam Actavis Group Contents of the pack and other information 
Kako čuvati Levetiracetam Actavis Group Sadržaj pakiranja i druge informacije
In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule. 
U tom je ispitivanju bolesnicima propisana oralna otopina u dnevnoj dozi od 20 mg/kg, 25 mg/kg, 40 mg/kg ili 50 mg/kg prema shemi titriranja ovisnoj o dobi.
In this study, levetiracetam dose was 3,000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses. 
Doza levetiracetama u toj studiji bila je 3000 mg na dan za odrasle i adolescente, a za djecu 60 mg/kg/dan, podjeljeno na dvije doze.
The daily dose must be individualised according to renal function. 
Dnevna doza određuje se za svakog bolesnika pojedinačno u skladu s bubrežnom funkcijom.
The efficacy analysis consisted of 109 patients who had at least 24 hours of video EEG in both baseline and evaluation periods. 
Analizom djelotvornosti obuhvaćeno je 109 bolesnika u kojih je snimljen barem 24-satni EEG na početku i na kraju razdoblja procjene.
There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. 
Postoje pojedina izvješća o smanjenoj učinkovitosti levetiracetama pri istodobnoj primjeni osmotskog laksativa makrogola i oralne primjene levetiracetama.
Hepatic failure, hepatitis 
Zatajenje jetre, hepatitis
In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. 
U bolesnika s teškim oštećenjem jetre, klirens kreatinina može lažno pokazati niži stupanj bubrežne insuficijencije.
Measure the appropriate dosage using the 10 ml syringe included in the package for patients of 4 years and above. 
Odgovarajuću dozu izmjerite pomoću štrcaljke od 10 ml koja se nalazi u pakiranju za bolesnike od navršene 4 godine nadalje.
The fractional removal of levetiracetam was 51% during a typical 4-hour dialysis session. 
Frakcijsko uklanjanje levetiracetama iznosi 51% tijekom uobičajene četverosatne dijalize.
• suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate); 
• samoubojstvo, poremećaj osobnosti (problemi u ponašanju), poremećaj mišljenja (sporo razmišljanje, nemogućnost koncentriranja);
Dose in children and adolescents 50 kg or more is the same as in adults. 
(2) Doza u djece i adolescenata od 50 kg ili više jednaka je kao u odraslih.
More than half of the subjects remained seizure free for 12 months (56.6% and 58.5% of subjects on levetiracetam and on carbamazepine CR respectively). 
Više od pola ispitanika 12 mjeseci nije imalo napadaje (56,6 % bolesnika koji su dobivali levetiracetam i 58,5 % ispitanika koji su dobivali karbamazepin s kontroliranim otpuštanjem).
What Levetiracetam Actavis Group looks like and contents of the pack 
Kako Levetiracetam Actavis Group izgleda i sadržaj pakiranja
Peak concentrations (Cmax) are typically 31 and 43 µg/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively. 
Vršna koncentracija (Cmax) uglavnom je 31 μg/ml nakon jedne doze od 1000 mg i 43 μg/ml nakon ponovljene doze od 1000 mg dva puta na dan.
Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. 
Nakon ponovljene primjene oralne doze (20 do 60 mg/kg/na dan) u djece s epilepsijom (4 do 12 godina) levetiracetam se brzo apsorbira.
Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. 
Uslijed potpune i linearne apsorpcije levetiracetama moguće je na temelju oralne doze izražene u mg/kg tjelesne težine predvidjeti razinu lijeka u plazmi.
A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1,800 mg/kg/day. 
Ispitivanje peri- i postnatalnog razvoja provedeno je u štakora dozama levetiracetama od 70, 350 i 1800 mg/kg/dan.
To measure the dosing quantity, use one hand to hold the dosing body and the other hand to pull up the plunger until you reach the graduation mark corresponding to the quantity in milliliters (ml) prescribed by your doctor (Figure 1). 
Kako biste odmjerili potrebnu dozu, s jednom rukom primite tijelo graduirane štrcaljke a s drugom izvucite njen klip do oznake koja odgovara količini u mililitrima (ml)
Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. 
Levetiracetam u dozi od 2000 mg na dan nije utjecao na farmakokinetiku digoksina i varfarina; protrombinsko vrijeme ostalo je nepromijenjeno.
• depression, hostility or aggression, anxiety, insomnia, nervousness or irritability; 
• depresija, netrpeljivost ili agresivnost, tjeskoba, nesanica, nervoza ili razdražljivost;
Creatinine clearance (ml/min/1.73m2) 
Klirens kreatinina (ml/min/1,73 m2)
The primary measure of effectiveness was the responder rate (percent of patients with ≥ 50% reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG. 
Primarna mjera učinkovitosti bila je stopa bolesnika s odgovorom (postotak bolesnika u kojih je dnevna prosječna učestalost napadaja smanjena za ≥ 50 % u odnosu na početno stanje) određena središnjim pregledavanjem 48-satnog video EEG-a od strane ocjenjivača koji nije znao tko je dobivao placebo, a tko lijek.
After oral administration the bitter taste of levetiracetam may be experienced. 
Nakon peroralne primjene može se očekivati gorak okus levetiracetama.
• Levetiracetam Actavis Group is used as a chronic treatment. 
• Levetiracetam Actavis Group se koristi za dugotrajno liječenje.
Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). 
Djelotvornost levetiracetama dokazana je u dvostruko slijepom i placebom kontroliranom ispitivanju u trajanju od 24 tjedna, koje je uključivalo odrasle, adolescente i ograničeni broj djece s idiopatskom generaliziranom epilepsijom s primarno generaliziranim toničko-kloničkim (PGTK) napadajima kod različitih sindroma (juvenilna mioklonična epilepsija, epilepsija s apsansima dječje i juvenilne dobi ili epilepsija s grand mal napadajima kod buđenja).
The pharmacokinetic profile is linear with low intra- and inter-subject variability. 
Farmakokinetički profil je linearan, a varijabilnost je niska i među različitim bolesnicima i za istog bolesnika.
Clear, faint yellowish-brown solution. 
Bistra, blijedo žućkasto-smeđa otopina.
Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. 
Levetiracetam malo ili umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima Uslijed mogućih razlika u osjetljivosti među pojedincima, u nekih bolesnika može se javiti somnolencija ili drugi simptomi vezani za središnji živčani sustav, osobito na početku liječenja ili nakon povećanja doze.
In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing). 
Bolesnici su u tom ispitivanju dobivali konstantnu dozu od 60 mg/kg/dan (doziranje dva puta na dan).
Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam. 
Probenecid (500 mg četiri puta na dan), inhibitor bubrežne tubularne sekrecije, inhibira bubrežni klirens glavnog metabolita levetiracetama, ali ne i samog levetiracetama.
The oral solution is the preferred formulation for use in infants and children under the age of 6 years. 
Oralna otopina najprikladniji je farmaceutski oblik za primjenu kod dojenčadi i djece mlađe od 6 godina.
Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1,200 and 1,800 mg/kg/day. 
Četiri ispitivanja embrio-fetalnog razvoja provedena su u kunića s dozama od 200, 600, 800, 1200 i 1800 mg/kg/dan.
A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study. 
20 mg/kg/dan titrirana je do 40 mg/kg/dan u dojenčadi u dobi od jednog do manje od 6 mjeseci, a doza od 25 mg/kg/dan titrirana je do 50 mg/kg/dan u dojenčadi i djece u dobi od 6 mjeseci do manje od 4
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, noninferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. 
Djelotvornost levetiracetama za samostalno liječenje dokazana je kod paralelnih grupa u dvostruko slijepoj usporedbi neinferiornosti s karbamazepinom s kontroliranim otpuštanjem (CR, engl. controlled release) na 576 bolesnika u dobi od 16 godina ili starijih s novo- ili nedavno dijagnosticiranom epilepsijom.
Drug reaction with eosinophilia and systemic symptoms (DRESS), Hypersensitivity (including angioedema and anaphylaxis) 
Reakcija na lijek s eozinofilijom i sistemskim simptomima (DRESS), preosjetljivost
43.6% of the levetiracetam treated patients and 19.6% of the patients on placebo were considered as responders. 
U 44,6 % bolesnika liječenih levetiracetamom i 19,6 % bolesnika koji su dobivali placebo, zapaženo je
Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. 
Opisani su rijetki slučajevi smanjenog broja krvnih stanica (neutropenija, agranulocitoza, leukopenija, trombocitopenija i pancitopenija) koji su povezani s primjenom levetiracetama, obično na početku liječenja.
Each ml contains 100 mg of levetiracetam. 
Jedan ml sadrži 100 mg levetiracetama.
• cough; 
• kašalj;
Steady-state is achieved after two days of a twice daily administration schedule. 
Stanje dinamičke ravnoteže postiže se nakon dva dana doziranja dva puta na dan.
You should not stop your treatment without discussing this with your doctor.A risk of birth defects for your unborn child cannot be completely excluded. 
Rizik od prirođenih mana za Vaše nerođeno dijete ne može se u potpunosti isključiti.
Dose in adults and adolescents from 16 years of age: 
Doza za odrasle i adolescente od 16. godine života:
Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours. 
Nakon primjene jedne oralne doze (20 mg/kg) u djece s epilepsijom (6 do 12 godina) poluvijek levetiracetama bilo je 6,0 sati.
Each ml contains 1.50 mg of methyl parahydroxybenzoate (E218), 0.15 mg of propyl parahydroxybenzoate (E216), 290 mg of maltitol liquid (E965), 3,26 mg propylene glycol (E 1520) and 0.25 mg of sodium. 
Jedan ml sadrži 1,50 mg metilparahidroksibenzoata (E218), 0,15 mg propilparahidroksibenzoata (E216), 290 mg tekućeg maltitola (E965), 3,26 mg propilenglikola (E1520) i 0,25 mg natrija.
Acute kidney injury 
Akutno oštećenje bubrega
Take the syringe and pull back the plunger a little way (Figure 2). 
Uzmite štrcaljku i malo izvucite klip (slika 2).
Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function: 
Prilagođavanje doze za odrasle bolesnike i adolescente teške više od 50 kg s oštećenom bubrežnom funkcijom
Following single dose administration (20 mg/kg) of a 100 mg/ml oral solution to epileptic children (1 month to 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing. 
Nakon primjene jedne doze (20 mg/kg) 100 mg/ml oralne otopine u djece s epilepsijom (1 mjesec do 4 godine) levetiracetam se brzo apsorbira te je vršna koncentracija u plazmi postignuta približno 1 sat nakon uzimanja lijeka.
The possible side effects of an overdose of Levetiracetam Actavis Group are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma. 
Moguće nuspojave predoziranja lijekom Levetiracetam Actavis Group su pospanost, uznemirenost, agresija, smanjena pozornost, smetnje disanja i koma.
Contact your doctor if you took more Levetiracetam Actavis Group than you should. 
Obavijestite liječnika ako ste uzeli veću količinu lijeka Levetiracetam Actavis Group nego što ste trebali.
Levetiracetam Actavis Group contains methyl parahydroxybenzoate, propyl parahydroxybenzoate, maltitol, propylene glycol and sodium. 
Levetiracetam Actavis Group sadrži metilparahidroksibenzoat, propilparahidroksibenzoat, maltitol, propilenglikol i natrij.
• muscle weakness, myalgia (muscle pain); 
• slabost mišića, mijalgija (bol u mišićima);
• vertigo (sensation of rotation); 
• vrtoglavica (osjećaj vrtnje);
In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants aged 1 month to less than 6 months. 
Kako bi se osiguralo točno doziranje to pakiranje treba propisivati dojenčadi u dobi od 1 mjeseca do manje od 6 mjeseci.
Levetiracetam Actavis Group oral solution contains propylene glycol (E1520). 
Levetiracetam Actavis Group oralna otopina sadrži propilenglikol (E1520).
This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product. 
Iz toga proizlazi da interakcija levetiracetama i sinaptičkog vezikularnog proteina 2A vjerojatno pridonosi antiepileptičkom mehanizmu djelovanja lijeka.
Other medicines and Levetiracetam Actavis Group 
Drugi lijekovi i Levetiracetam Actavis Group
Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. 
Ovisno o kliničkom odgovoru i podnošljivosti lijeka, doza se može povećati do 30 mg/kg dva puta na dan.
Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam. 
Primjena levetiracetama zajedno s digoksinom, oralnim kontraceptivima i varfarinom nije utjecala na farmakokinetiku levetiracetama.
Instruction for use for 1 ml and 3 ml syringes with an adaptor 
Upute za uporabu za štrcaljke od 1 ml i 3 ml s nastavkom
No tissue distribution data are available in humans. 
Nema podataka o raspodjeli ovog lijeka u tkivima kod ljudi.
Levetiracetam Actavis Group oral solution also contains maltitol. 
Levetiracetam Actavis Group oralna otopina također sadrži maltitol.
Pancytopenia, neutropenia, agranulocytosis 
Pancitopenija, neutropenija, agranulocitoza
72.2% of the levetiracetam treated patients and 45.2% of the patients on placebo had a 50% or greater decrease in the frequency of PGTC seizures per week. 
U 72,2 % bolesnika liječenih levetiracetamom i 45,2 % bolesnika koji su dobivali placebo primijećeno je 50 %-tno ili više smanjenje učestalosti PGTK napadaja tjedno.
Turn the bottle the right way up and remove the syringe (Figure 8). 
Vratite bocu u uspravan položaj i uklonite štrcaljku (slika 8).
Levetiracetam Actavis Group is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. 
Levetiracetam Actavis Group je indiciran kao monoterapija u liječenju parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih i adolescenata od 16. godine života s novodijagnosticiranom epilepsijom.
Levetiracetam Actavis Group oral solution includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). 
Levetiracetam Actavis Group oralna otopina sadrži metilparahidroksibenzoat (E218) i propilparahidroksibenzoat (E216) koji mogu izazvati alergijske reakcije (koje mogu biti i odgođene).
If you take more Levetiracetam Actavis Group than you should 
Ako uzmete više lijeka Levetiracetam Actavis Group nego što ste trebali
Levetiracetam Actavis Group is not indicated in children and adolescents below 16 years on its own (monotherapy). 
U djece i adolescenata mlađih od 16 godina Levetiracetam Actavis Group se ne primjenjuje samostalno (monoterapija).
Infants should start the treatment with Levetiracetam Actavis Group 100 mg/ml oral solution. 
Dojenčad treba započeti liječenje sa Levetiracetam Actavis Group 100 mg/ml oralnom otopinom.
Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. 
Promjena doze ne smije premašiti povećanja ili smanjenja za 10 mg/kg dva puta na dan svaka dva tjedna.
From 50 kg (2) 
Iznad 50 kg (2)
500 to 1,000 mg once daily (2) 
500 do 1000 mg jedanput na dan (2)
Levetiracetam Actavis Group 100 mg/ml oral solution contains 3,26 mg propylene glycol (E1520) in each ml. 
Levetiracetam Actavis Group 100 mg/ml oralna otopina sadrži 3,26 mg propilenglikola (E1520) u jednom ml.
You should not drive or use machines until it is established that your ability to perform such activities is not affected. 
Ne smijete voziti ili se koristiti strojevima dok se ne utvrdi da uzimanje lijeka Levetiracetam Actavis Group ne utječe na Vaše sposobnosti za to.
Depression, hostility/ aggression, anxiety, insomnia, nervousness/irritability 
Depresija, netrpeljivost/ agresivnost, anksioznost, nesanica, nervoza/razdražljivost
Specialist advice should be given to women who are of childbearing potential. 
Žene reproduktivne dobi treba savjetovati specijalist.
Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. 
Ovisno o kliničkom odgovoru i podnošljivosti lijeka, dnevna doza može se povećati do 1500 mg dva puta na dan.
Dose and frequency (1) Infants 1 to less than 6 months 
Doza i učestalost primjene (1) Dojenčad od 1 mjeseca do manje od 6 mjeseci
Dose changes should not exceed increases or decreases of 7 mg/kg twice daily every two weeks. 
Promjena doze ne smije premašiti povećanja ili smanjenja za 7 mg/kg dva puta na dan svaka dva tjedna.
The other ingredients are: sodium citrate, citric acid monohydrate, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), ammonium glycyrrhizate, glycerin, glycerol (E422), maltitol liquid (E965), acesulfame potassium (E950), grape flavour (contains propylene glycol), purified water. 
Drugi sastojci su: natrijev citrat, citratna kiselina hidrat, metilparahidroksibenzoat (E218), propilparahidroksibenzoat (E216), amonijev glicirizat, glicerin, glicerol (E422), tekući maltitol (E965), acesulfamkalij (E950), aroma grožđa (sadrži propilenglikol), pročišćena voda.
In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. 
U pedijatrijskih bolesnika (4 do 16 godina života) djelotvornost levetiracetama dokazana je u dvostruko slijepom i placebom kontroliranom ispitivanju koje je trajalo 14 dana i uključivalo 198 bolesnika.
For children aged 1 month to less than 6 months. 
Za djecu u dobi od 1 mjeseca do manje od 6 mjeseci.
Two embryo-foetal development (EFD) studies were performed in rats at 400, 1,200 and 3,600 mg/kg/day. 
Provedena su dva ispitivanja embrio-fetalnog razvoja (engl. embryo-fetal development, EFD) u štakora s dozama od 400, 1200 i 3600 mg/kg/dan.
Balkanpharma-Troyan AD 1 Krayrechna Str, Troyan 5600 
Balkanpharma-Troyan AD 1 Krayrechna Str,
The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. 
Hrana ne utječe na opseg apsorpcije levetiracetama, ali blago smanjuje brzinu apsorpcije.
The active substance is called levetiracetam. 
Djelatna tvar je levetiracetam.
Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. 
Levetiracetam i srodni analozi s različitim se afinitetom vežu za sinaptički vezikularni protein 2A, a to je, u mišjem modelu audiogene epilepsije, povezano s potencijalom zaštite od napada.
In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam. 
U osoba s blagim i umjerenim oštećenjem jetre klirens levetiracetama nije bitno promijenjen.
The maximum dose is 1,500 mg twice daily. 
Maksimalna je doza 1500 mg dva puta na dan.
Open the bottle and push the syringe adaptor firmly into the bottle neck (Figure 1). 
Otvorite bocu i dobro utisnite nastavak za štrcaljku na vrat boce (slika 1).